TScan Therapeutics' (TCRX) "Outperform" Rating Reaffirmed at Wedbush

TScan Therapeutics (NASDAQ:TCRX - Get Free Report)'s stock had its "outperform" rating reissued by analysts at Wedbush in a report issued on Wednesday,RTT News reports. They currently have a $7.00 price objective on the stock. Wedbush's price objective points to a potential upside of 253.54% from the company's previous close.

Several other brokerages also recently issued reports on TCRX. HC Wainwright reissued a "buy" rating and set a $15.00 target price on shares of TScan Therapeutics in a research note on Wednesday, December 11th. Needham & Company LLC cut their price objective on shares of TScan Therapeutics from $11.00 to $9.00 and set a "buy" rating for the company in a report on Wednesday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $9.20.

TScan Therapeutics Price Performance

Shares of NASDAQ TCRX traded down $0.10 during midday trading on Wednesday, reaching $1.98. The stock had a trading volume of 207,206 shares, compared to its average volume of 312,081. The company has a market capitalization of $105.67 million, a price-to-earnings ratio of -1.87 and a beta of 0.91. TScan Therapeutics has a 12-month low of $1.82 and a 12-month high of $9.69. The stock has a 50-day moving average of $2.41 and a 200-day moving average of $4.00. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56.

Remove Ads

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.02). The business had revenue of $0.67 million during the quarter, compared to analysts' expectations of $1.43 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. As a group, research analysts anticipate that TScan Therapeutics will post -1.12 EPS for the current fiscal year.

Institutional Trading of TScan Therapeutics

Several hedge funds have recently modified their holdings of the company. Brown Brothers Harriman & Co. raised its stake in TScan Therapeutics by 88.2% during the third quarter. Brown Brothers Harriman & Co. now owns 143,051 shares of the company's stock valued at $712,000 after purchasing an additional 67,027 shares in the last quarter. Great Point Partners LLC increased its holdings in shares of TScan Therapeutics by 8.0% in the 3rd quarter. Great Point Partners LLC now owns 1,016,375 shares of the company's stock worth $5,062,000 after buying an additional 75,544 shares during the last quarter. MetLife Investment Management LLC raised its position in shares of TScan Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 23,363 shares of the company's stock valued at $116,000 after buying an additional 13,164 shares in the last quarter. Checkpoint Capital L.P. bought a new position in shares of TScan Therapeutics in the 3rd quarter valued at about $4,110,000. Finally, Jacobs Levy Equity Management Inc. purchased a new position in TScan Therapeutics in the third quarter worth about $515,000. 82.83% of the stock is owned by hedge funds and other institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.